Latest Ratios: P/E Ratio -0.2x · EV/EBITDA N/A · ROE -49.4%. (2011–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $7M | $14M | $145M | $173M | $295M | $367M | $68M | $25M | $31M | $29M | $57M |
| Enterprise Value | $4M | $11M | $142M | $147M | $254M | $298M | $55M | $18M | $22M | $26M | $57M |
| P/E Ratio → | -0.18 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.09 | 0.18 | 1.96 | 1.89 | 2.85 | 2.77 | 2.02 | 1.04 | 1.10 | 1.31 | 3.40 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -49.4% | -49.4% | -47.3% | -33.4% | -28.5% | -27.8% | -60.5% | -59.6% | -50.3% | -53.6% | -102.9% |
| ROA | -30.2% | -30.2% | -35.5% | -29.9% | -26.2% | -24.8% | -48.2% | -51.9% | -45.2% | -44.8% | -73.1% |
| ROIC | -39.5% | -39.5% | -46.1% | -43.1% | -39.7% | -41.7% | -70.2% | -65.9% | -54.8% | -41.5% | -70.6% |
| ROCE | -46.2% | -46.2% | -47.0% | -35.4% | -26.9% | -26.4% | -55.3% | -59.7% | -55.4% | -51.6% | -92.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.00 | 0.01 | 0.01 | 0.01 | 0.04 | 0.01 | 0.01 | 0.01 | 0.04 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.03 | -0.04 | -0.28 | -0.40 | -0.52 | -0.37 | -0.32 | -0.32 | -0.14 | 0.02 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -143.46 | -143.46 | — | — | -131.52 | -2125.99 | -1118.64 | -945.43 | -790.55 | -11.74 | -828.25 |
Net cash position: cash ($4M) exceeds total debt ($2M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.62 | 0.62 | 0.40 | 5.95 | 9.84 | 18.28 | 3.41 | 1.72 | 3.16 | 1.39 | 0.17 |
| Quick Ratio | 0.13 | 0.13 | 0.17 | 5.95 | 9.84 | 18.28 | 3.41 | 1.72 | 3.16 | 1.39 | 0.17 |
| Cash Ratio | 0.09 | 0.09 | 0.09 | 4.58 | 9.21 | 17.60 | 3.38 | 1.71 | 2.88 | 1.30 | 0.06 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | 0.01 | 0.01 | 0.03 | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $11M | $12M | $10M | $10M | $7M | $3M | $1M | $715458 | $365500 | $241547 |
Imminent liquidity and dilution
As reported in financial statements, Citius Pharmaceuticals' gross margin of -22.9% in 2026Q2 highlights the absence of a scalable commercial product, confirming that the firm's current earning power remains deeply negative while it continues to prioritize clinical trial execution over operational profitability or cost-efficient revenue generation.
The persistent negative operating margins suggest that the company is currently unable to cover its fixed R&D and administrative overhead through its limited revenue streams. Investors should monitor whether the transition to commercialization for its lead assets can reverse these trends, as the current cost structure appears unsustainable without significant external capital injections.
Based on recent SEC filings, the company's ROIC has deteriorated to -31.6% in 2026Q2, reflecting a significant decay in the efficiency of invested capital as the firm continues to burn through resources to fund its late-stage clinical pipeline without achieving a corresponding return on its research expenditures.
The consistent negative ROIC trend indicates that the company is currently destroying shareholder value rather than compounding it, which is typical for pre-revenue biotech firms but nonetheless concerning given the prolonged timeline of its clinical trials. This performance suggests that the firm's capital allocation strategy is heavily reliant on future regulatory success rather than current operational efficiency.
According to the provided quarterly data, the company's current ratio has plummeted to 0.58 in 2026Q2, indicating that liquid assets are now insufficient to cover short-term obligations, which warrants extreme caution regarding the firm's ability to sustain its current clinical development pace without immediate and potentially dilutive financing.
The rapid decline in the quick ratio from 6.75 in 2024Q3 to 0.16 in 2026Q2 highlights a severe liquidity crunch that leaves the company with little margin for error in its regulatory or clinical timelines. This position suggests that the firm is highly vulnerable to any unexpected delays in the FDA approval process or further cost overruns.
As indicated by historical financial statements, the company's cash conversion cycle reached 684 days in 2026Q2, a metric that, while common for developmental-stage firms, underscores the extreme disconnect between the firm's operational activities and its ability to generate cash from its core research and development pipeline.
The erratic nature of the company's inventory and accounts payable turnover suggests that working capital management is currently driven by the timing of clinical trial vendor payments rather than standard commercial operations. This lack of operational rhythm makes it difficult to assess the firm's underlying efficiency until it achieves a consistent, revenue-generating commercial footprint.
Based on the company's reported P/B ratio of 0.08, investors often misinterpret this as a deep-value signal, failing to recognize that in a pre-revenue biotech context, book value is largely composed of intangible assets and R&D spend that may hold little liquidation value if clinical trials fail.
The P/B ratio is fundamentally flawed for Citius Pharmaceuticals because it ignores the binary nature of the company's clinical assets, which are either worth significant future cash flows or effectively zero upon regulatory rejection. Analysts should instead focus on the cash-burn-to-approval-timeline ratio to better assess the firm's survival probability rather than relying on balance sheet metrics that do not reflect the true economic risk of the pipeline.
Includes 30+ ratios · 15 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CTXR stock.
Citius Pharmaceuticals, Inc.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
Citius Pharmaceuticals, Inc.'s return on equity (ROE) is -49.4%. The historical average is -51.3%.
Based on historical data, Citius Pharmaceuticals, Inc. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.